Subjects in the combination arm will receive voriconazole and anidulafungin in combination for 2-4 weeks followed by voriconazole monotherapy to complete 6-12 weeks of therapy.

Subjects in the monotherapy arm will receive voriconazole monotherapy for 6-12 weeks of therapy.

For Children aged 2-11 years and adolescents aged 12-14 years weighing <50 kg:

Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.

For adolescents aged 12-17 years, excluding 12-14-year-olds weighing <50kg:

Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.

Voriconazole therapy is to be given for 6-12 weeks.